Hi All:
Raven and I have been discussing the possible approval of a new osteo med, and I thought I would start a new thread on it so everyone can find it. Keep in mind that this drug is in Phase III clinical trials, and just recently outperformed Fosomax in a head to head study, so we don't know yet if it will make it through the requirements of the FDA, but a proposed new drug application is scheduled for sometime in 2009 barring any set backs. The new drug is Denosumab or Dmab for you acronym lovers; it's made by Amgen in Thousand Oaks CA, and is a fully human monoclonal antibody, and NOT a bisphosphonate. Since Fosomax is going off patent, and if Dmab is approved, there may be a price concern, but this is completely speculative since we have no idea what the price would be "if" it is approved.
I've posted a link below, but unfortunately it wasn't the one I was actually looking for that had a greater explanation of the trials and how the drug works. If you want to know more you can query Amgen + Denosumab or Densomab v Fosamax (alendronate)" leaving out the words in parens. As of Jan 08, it's slated for a twice yearly subq injection, but I would imagine that could change if final approval is received. You can find quite a bit on this drug at various places, if you are interested. If interested, I would suggest seeking the newest articles you can find, since the info on this drug has changed over the years of it's clinical trials process. Medscape has a good article on it, but it's from 2005, so if you are registered there you can easily find it, or maybe a newer one. If you aren't registered, I would recommend it since they have great articles-plus it's free.
I will be finishing Forteo at the end of June and as yet have not decided what to take, but I'm leaning towards Evista because I had trouble with BP's (Bisphosphonates). If Denosumab gets approval I would consider switching to that since Evista works pretty slowly, and I have made great gains on Forteo that I don't want to loose.
Good luck to all...
http://www.mskreport.com/articles.cfm?articleID=2772



Add to the discussion